Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Shore on Unique Challenges in Nonmetastatic CRPC

August 3rd 2020

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer

July 30th 2020

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC

July 30th 2020

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Dr. Shore on Cardio-Oncology Strategies in Prostate Cancer

July 30th 2020

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.

FDA Provides Regulatory Clarity on Phase 3 Trial Design for VERU-111 in mCRPC

July 29th 2020

The FDA has provided regulatory clarity on the design of the pivotal phase 3 trial examining the first-in-class oral, oral, selective antitubulin agent VERU-111 in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

July 29th 2020

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer

July 29th 2020

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC

July 28th 2020

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Delayed LHRH Agonist Dosing Doubles Castration Levels in Prostate Cancer

July 28th 2020

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.

Salvage Lymph Node Dissection Shows Suboptimal Benefit in Node-Positive Prostate Cancer

July 24th 2020

Findings from a recent study published in European Urology show that salvage lymph node dissection alone is inadequate intervention for patients with prostate cancer and nodal recurrence.

Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate Cancer

July 23rd 2020

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Shore Speaks to Updates Showcasing Benefits, Safety of Darolutamide in Nonmetastatic CRPC

July 23rd 2020

Neal Shore, MD, discusses the significantly improved overall survival in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

July 22nd 2020

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

July 20th 2020

Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.

Dr. Gafita on the Rationale to Evaluate 177Lu-PSMA-617 in mCRPC

July 17th 2020

Andrei Gafita, MD, discusses the rationale to evaluate lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Sternberg Showcases Promising PROSPER Data With Enzalutamide in Nonmetastatic CRPC

July 16th 2020

Cora N. Sternberg, MD, discusses the data seen with enzalutamide in nonmetastatic castration-resistant prostate cancer, the updated survival results from the phase 3 PROSPER trial, and how she chooses among the agents available in the space.

Niraparib/Radium-223 Combo Shows Tolerability in Early-Phase CRPC Trial

July 16th 2020

William K. Kelly, DO, discusses the early data seen with radium-223 plus niraparib and the next steps for this regimen in castration-resistant prostate cancer.

Patient Outcomes Support Cabazitaxel Over Standard in mCRPC

July 14th 2020

Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.

Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate Cancer

July 14th 2020

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC

July 13th 2020

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.